Richard Reynolds

Prof. Richard Reynolds

Imperial College London
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RMRoberta Magliozzi
Roberta Magliozzi
OHOwain Howell
Owain Howell
CRCheryl Reeves
Cheryl Reeves
FRFederico Roncaroli
Federico Roncaroli
RNRichard Nicholas
Richard Nicholas
RRRichard Reynolds
Richard Reynolds

17 July 2019 in Nature
Verified
Journal Article
Closed access
PDF file
LSLucas Schirmer
Lucas Schirmer
DVDmitry Velmeshev
Dmitry Velmeshev
SHStaffan Holmqvist
Staffan Holmqvist
MKMax Kaufmann
Max Kaufmann
SWSebastian Werneburg
Sebastian Werneburg
DRDavid H. Rowitch
David H. Rowitch

1 September 2018 in Cell
Verified
Journal Article
Open access
IJIvan Jelcic
Ivan Jelcic
FNFaiez Al Nimer
Faiez Al Nimer
JWJian Wang
Jian Wang
VLVerena Lentsch
Verena Lentsch
RPRaquel Planas
Raquel Planas
RMRoland Martin
Roland Martin
Multiple sclerosis is an autoimmune disease that is caused by the interplay of genetic, particularly the HLA-DR15 haplotype, and environmental risk factors. How these etiologic factors contribute to generating an autoreactive CD4+ T cell repertoire is not clear. Here, we demonstrate that self-reactivity, defined as "autoproliferation" of peripheral Th1 cells, is elevated in patients carrying the HLA-DR15 haplotype. Autoproliferation is mediated by memory B cells in a HLA-DR-dependent manner. Depletion of B cells in vitro and therapeutically in vivo by anti-CD20 effectively reduces T cell autoproliferation. T cell receptor deep sequencing showed that in vitro autoproliferating T cells are enriched for brain-homing T cells. Using an unbiased epitope discovery approach, we identified RASGRP2 as target autoantigen that is expressed in the brain and B cells. These findings will be instrumental to address important questions regarding pathogenic B-T cell interactions in multiple sclerosis and possibly also to develop novel therapies.

20 February 2015 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
Massimiliano CalabreseMassimiliano Calabrese
Massimiliano Calabrese
RMRoberta Magliozzi
Roberta Magliozzi
OCOlga Ciccarelli
Olga Ciccarelli
JGJeroen J. G. Geurts
Jeroen J. G. Geurts
RRRichard Reynolds
Richard Reynolds
RMRoland Martin
Roland Martin

23 April 2018 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
RMRoberta Magliozzi
Roberta Magliozzi
OHOwain Howell
Owain Howell
RNRichard Nicholas
Richard Nicholas
CCCarolina Cruciani
Carolina Cruciani
MCMarco Castellaro
Marco Castellaro
Massimiliano CalabreseMassimiliano Calabrese
Massimiliano Calabrese
Objective: Gray matter (GM) damage and meningeal inflammation have been associated with early disease onset and a more aggressive disease course in multiple sclerosis (MS), but can these changes be identified in the patient early in the disease course?Methods: To identify possible biomarkers linking meningeal inflammation, GM damage, and disease severity, gene and protein expression were analyzed in meninges and cerebrospinal fluid (CSF) from 27 postmortem secondary progressive MS and 14 control cases. Combined cytokine/chemokine CSF profiling and 3T magnetic resonance imaging (MRI) were performed at diagnosis in 2 independent cohorts of MS patients (35 and 38 subjects) and in 26 non‐MS patients.Results: Increased expression of proinflammatory cytokines (IFNγ, TNF, IL2, and IL22) and molecules related to sustained B‐cell activity and lymphoid‐neogenesis (CXCL13, CXCL10, LTα, IL6, and IL10) was detected in the meninges and CSF of postmortem MS cases with high levels of meningeal inflammation and GM demyelination. Similar proinflammatory patterns, including increased levels of CXCL13, TNF, IFNγ, CXCL12, IL6, IL8, and IL10, together with high levels of BAFF, APRIL, LIGHT, TWEAK, sTNFR1, sCD163, MMP2, and pentraxin III, were detected in the CSF of MS patients with higher levels of GM damage at diagnosis.Interpretation: A common pattern of intrathecal (meninges and CSF) inflammatory profile strongly correlates with increased cortical pathology, both at the time of diagnosis and at death. These results suggest a role for detailed CSF analysis combined with MRI as a prognostic marker for more aggressive MS. Ann Neurol 2018 Ann Neurol 2018;83:739–755

6 October 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
HGHélène O. B. Gautier
Hélène O. B. Gautier
KEKimberley A. Evans
Kimberley A. Evans
KVKatrin Volbracht
Katrin Volbracht
RJRachel James
Rachel James
SSSergey Sitnikov
Sergey Sitnikov
RKRagnhildur T Káradóttir
Ragnhildur T Káradóttir
Myelin regeneration can occur spontaneously in demyelinating diseases such as multiple sclerosis (MS). However, the underlying mechanisms and causes of its frequent failure remain incompletely understood. Here we show, using an in-vivo remyelination model, that demyelinated axons are electrically active and generate de novo synapses with recruited oligodendrocyte progenitor cells (OPCs), which, early after lesion induction, sense neuronal activity by expressing AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)/kainate receptors. Blocking neuronal activity, axonal vesicular release or AMPA receptors in demyelinated lesions results in reduced remyelination. In the absence of neuronal activity there is a ∼6-fold increase in OPC number within the lesions and a reduced proportion of differentiated oligodendrocytes. These findings reveal that neuronal activity and release of glutamate instruct OPCs to differentiate into new myelinating oligodendrocytes that recover lost function. Co-localization of OPCs with the presynaptic protein VGluT2 in MS lesions implies that this mechanism may provide novel targets to therapeutically enhance remyelination.